• Register
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.


Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.


Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth.

BACKGROUND: In opioid dependent youth there is substantial attrition from medication-assisted treatment. If youth at risk for attrition can be identified at treatment entry or early in treatment, they can be targeted for interventions to help retain them in treatment. METHODS: Opioid dependent adolescents and young adults (n=152), aged 15-21, were randomized to 12 weeks (BUP, n=74) or 2 weeks of detoxification (DETOX, n=78) with buprenorphine/naloxone (Bup/Nal), both in combination with 12 weeks of psychosocial treatment. Baseline and early treatment related predictors of treatment attrition were identified in each group using bivariate and multivariate logistic regression. RESULTS: In the DETOX group 36% left between weeks 2 and 4, at the end of the dose taper, while in the BUP group only 8% left by week 4. In the BUP group, early adherence to Bup/Nal, early opioid negative urines, use of any medications in the month prior to treatment entry, and lifetime non-heroin opioid use were associated with retention while prior 30-day hallucinogen use was associated with attrition. In the DETOX group, only use of sleep medications was associated with retention although not an independent predictor. A broad range of other pre-treatment characteristics was unrelated to attrition. CONCLUSIONS: Prompt attention to those with early non-adherence to medication or an early opioid positive urine, markers available in the first 2 weeks of treatment, may improve treatment retention. Extended Bup/Nal treatment appeared effective in improving treatment retention for youth with opioid dependence across a wide range of demographics, and pre-treatment clinical characteristics.

Pubmed ID: 22626890


  • Warden D
  • Subramaniam GA
  • Carmody T
  • Woody GE
  • Minhajuddin A
  • Poole SA
  • Potter J
  • Fishman M
  • Bogenschutz M
  • Patkar A
  • Trivedi MH


Addictive behaviors

Publication Data

September 25, 2012

Associated Grants

  • Agency: NIDA NIH HHS, Id: K05 DA017009
  • Agency: NIDA NIH HHS, Id: K12 DA000357
  • Agency: NIDA NIH HHS, Id: K12-DA000357
  • Agency: NIDA NIH HHS, Id: KO5 DA-17009
  • Agency: NIDA NIH HHS, Id: U10 DA013043
  • Agency: NIDA NIH HHS, Id: U10 DA015833
  • Agency: NIDA NIH HHS, Id: U10 DA020024
  • Agency: NIDA NIH HHS, Id: U10-DA020024
  • Agency: NIDA NIH HHS, Id: U10-DA13043

Mesh Terms

  • Adolescent
  • Buprenorphine
  • Female
  • Humans
  • Male
  • Medication Adherence
  • Naloxone
  • Narcotic Antagonists
  • Opioid-Related Disorders
  • Risk Factors
  • Treatment Outcome
  • Young Adult